Ignite Creation Date:
2024-05-05 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 9:38 AM
Study NCT ID:
NCT00560963
Status:
COMPLETED
Last Update Posted:
2020-12-21
First Post:
2007-11-19
Brief Title:
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus RAD001 and Gemcitabine
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Combination of Antiangiogenic Therapy Using the mTOR-inhibitor RAD001 and Low Dose Chemotherapy for Locally Advanced andor Metastatic Pancreatic Cancer - a Dose Finding Study
Status:
COMPLETED
Status Verified Date:
2012-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A dose finding study in locally advanced andor metastatic pancreatic cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None